Literature DB >> 8167797

Is vaccination against hepatitis B efficient? A review of world literature.

T Jefferson1, V Demicheli.   

Abstract

We report on the result of a study aimed at assessing the variability of assumptions upon which economic models for the introduction of vaccination against Hepatitis B are based, the conclusions reached and define a minimum set of methodological standards upon which future economic studies on vaccines should be based. We identified 116 published and unpublished works by Medline literature searches, consulting private databases and corresponding with all authors and researchers active in economic evaluation of vaccines. All works were assessed but we included in our review only those which were original economic analyses (90 studies). Principal epidemiological and economic variables were extracted and compared where possible. Rough manipulations were carried out to make the data comparable. We found profound variability on the main parameters of the efficiency equation (disease incidence, costing methods, use of marginal theory, discounting and study time-span, sensitivity analysis and reporting methods). We also found inconsistencies in definition and study design in 38% of a subset of studies. Although we found scarce decision-making impact, we believe that due to uncertain or unclear methodology, few studies reach valid conclusions. In future decisions may be based on biased evidence and scarce resources committed to untested programmes. There is an urgent need to standardise study methods and define a common set of procedures.

Entities:  

Mesh:

Year:  1994        PMID: 8167797     DOI: 10.1002/hec.4730030105

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  12 in total

1.  Challenges to the economic evaluation of new biotechnological interventions in healthcare.

Authors:  J Mason
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

2.  Quality of economic evaluations in health care.

Authors:  Tom Jefferson; Vittorio Demicheli
Journal:  BMJ       Date:  2002-02-09

3.  Economic evaluation of influenza vaccination and economic modelling. Can results be pooled?

Authors:  T Jefferson; V Demicheli
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

4.  Assessing quality of economic submissions to the BMJ.

Authors:  T Jefferson; V Demicheli; V Entwistle
Journal:  BMJ       Date:  1995-08-05

Review 5.  Analysis and interpretation of cost data in randomised controlled trials: review of published studies.

Authors:  J A Barber; S G Thompson
Journal:  BMJ       Date:  1998-10-31

6.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03

7.  Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.

Authors:  J Lord; M J Thomason; P Littlejohns; R A Chalmers; M D Bain; G M Addison; A H Wilcox; C A Seymour
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

8.  Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain.

Authors:  F Antoñanzas; R Garuz; J Rovira; F Antón; C Trinxet; E Navas; L Salleras
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

9.  Prevalence study of different hepatitis markers among pregnant Albanian refugees in Greece.

Authors:  A Malamitsi-Puchner; S Papacharitonos; D Sotos; L Tzala; M Psichogiou; A Hatzakis; A Evangelopoulou; S Michalas
Journal:  Eur J Epidemiol       Date:  1996-06       Impact factor: 8.082

Review 10.  Methodological quality of economic modelling studies. A case study with hepatitis B vaccines.

Authors:  T Jefferson; V Demicheli
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.